Dimensional Fund Advisors LP Boosts Stock Position in Bioventus Inc. (NYSE:BVS)

Dimensional Fund Advisors LP grew its stake in Bioventus Inc. (NYSE:BVS - Free Report) by 55.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 427,422 shares of the company's stock after purchasing an additional 152,311 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.53% of Bioventus worth $4,488,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. JPMorgan Chase & Co. raised its position in Bioventus by 228.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company's stock valued at $3,032,000 after buying an additional 176,442 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Bioventus by 11.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 435,344 shares of the company's stock valued at $4,571,000 after purchasing an additional 45,182 shares during the last quarter. Franklin Resources Inc. bought a new position in shares of Bioventus during the third quarter valued at about $1,011,000. Principal Financial Group Inc. boosted its holdings in Bioventus by 9.4% during the fourth quarter. Principal Financial Group Inc. now owns 19,228 shares of the company's stock worth $202,000 after purchasing an additional 1,652 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Bioventus by 18.7% in the 4th quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company's stock worth $25,852,000 after purchasing an additional 388,174 shares in the last quarter. Institutional investors own 62.94% of the company's stock.

Insiders Place Their Bets

In other Bioventus news, CFO Mark Leonard Singleton sold 3,875 shares of the business's stock in a transaction on Friday, April 11th. The stock was sold at an average price of $7.57, for a total value of $29,333.75. Following the sale, the chief financial officer now directly owns 141,088 shares in the company, valued at $1,068,036.16. The trade was a 2.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Anthony D'adamio sold 4,380 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $44,632.20. Following the transaction, the senior vice president now directly owns 118,178 shares in the company, valued at $1,204,233.82. This represents a 3.57% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 24,208 shares of company stock valued at $226,138. Company insiders own 32.90% of the company's stock.

Bioventus Stock Performance

Shares of NYSE:BVS traded up $0.25 during midday trading on Friday, reaching $6.79. The company had a trading volume of 431,934 shares, compared to its average volume of 454,578. The stock has a market cap of $556.40 million, a P/E ratio of -11.13 and a beta of 0.95. The company's 50 day moving average price is $8.17 and its 200 day moving average price is $9.91. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a 52-week low of $5.28 and a 52-week high of $14.38.

Analyst Upgrades and Downgrades

BVS has been the topic of several recent analyst reports. Craig Hallum set a $15.00 target price on shares of Bioventus and gave the stock a "buy" rating in a research report on Wednesday, May 7th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $15.00 price target on shares of Bioventus in a research report on Monday, March 17th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.